Targeting B cells in treatment of autoimmunity.
Targeting B cells in treatment of autoimmunity.
复制标题
DOI：
10.1016/j.coi.2016.09.003
复制
发表时间：
2016-12
影响因子：
7
通讯作者：
Cambier JC
中科院分区：
文献类型：
--
作者：
Franks SE;Getahun A;Hogarth PM;Cambier JC
B 细胞已成为自身免疫治疗干预的有效靶标，其中最终效应器是抗体，而 T 细胞是炎症的主要驱动因素。这一原理的证明主要来自于利妥昔单抗（一种抗 CD20 单克隆抗体，可消耗 B 细胞）在各种自身免疫环境中的功效研究。这些成功激发了人们努力开发针对特定需求的更有效的抗 CD20，以及抑制 B 细胞功能且不存在 B 细胞耗竭固有风险的生物制品和小分子。在此我们回顾一下 B 细胞靶向治疗自身免疫的现状。
B cells have emerged as effective targets for therapeutic intervention in autoimmunities in which the ultimate effectors are antibodies, as well as those in which T cells are primary drivers of inflammation. Proof of this principle has come primarily from studies of the efficacy of Rituximab, an anti-CD20 mAb that depletes B cells, in various autoimmune settings. These successes have inspired efforts to develop more effective anti-CD20s tailored for specific needs, as well as biologicals and small molecules that suppress B cell function without the risks inherent in B cell depletion. Here we review the current status of B cell-targeted therapies for autoimmunity.